565 related articles for article (PubMed ID: 33776367)
21. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ
Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893
[TBL] [Abstract][Full Text] [Related]
22. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
23. Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions.
Tapia Rico G; Li M; Pavlakis N; Cehic G; Price TJ
Cancer Treat Rev; 2018 May; 66():1-6. PubMed ID: 29602040
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
Faggiano A; Di Maio S; Mocerino C; Ottaviano M; De Divitiis C; Guarnotta V; Dolce P; Modica R; Puliafito I; Tozzi L; Di Sarno A; Leo S; Riccardi F; Palmieri G; Tafuto S; Bianco A; Badalamenti G; Colao A;
Endocrine; 2019 Nov; 66(2):417-424. PubMed ID: 30875056
[TBL] [Abstract][Full Text] [Related]
25. Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey.
Falconi M; Fazio N; Ferone D; Versari A
Expert Opin Pharmacother; 2020 Dec; 21(18):2317-2324. PubMed ID: 32990061
[TBL] [Abstract][Full Text] [Related]
26. The role of multimodal treatment in patients with advanced lung neuroendocrine tumors.
Fazio N; Ungaro A; Spada F; Cella CA; Pisa E; Barberis M; Grana C; Zerini D; Bertani E; Ribero D; Funicelli L; Bonomo G; Ravizza D; Guarize J; De Marinis F; Petrella F; Del Signore E; Pelosi G; Spaggiari L
J Thorac Dis; 2017 Nov; 9(Suppl 15):S1501-S1510. PubMed ID: 29201453
[TBL] [Abstract][Full Text] [Related]
27. Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours - single-centre experience of two cases.
La Salvia A; Brizzi MP; Muratori L; Trevisi E; Di Maio M; Scagliotti GV
Endokrynol Pol; 2019; 70(4):380-383. PubMed ID: 30359462
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
Roquin G; Baudin E; Lombard-Bohas C; Cadiot G; Dominguez S; Guimbaud R; Niccoli P; Legoux JL; Mitry E; Rohmer V; Ruszniewski P; Walter T; Ducreux M; Couvelard A; Scoazec JY; Ramond-Roquin A; Caroli-Bosc FX; Hentic O
Neuroendocrinology; 2018; 106(1):38-46. PubMed ID: 28152531
[TBL] [Abstract][Full Text] [Related]
29. [Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system].
Auernhammer CJ; Spitzweg C; Böck S; Knösel T; Bartenstein P
Dtsch Med Wochenschr; 2019 Oct; 144(20):1390-1395. PubMed ID: 31594011
[TBL] [Abstract][Full Text] [Related]
30. [Neuroendocrine tumours of the GI tract--data from the German NET Registry].
Begum N; Maasberg S; Plöckinger U; Anlauf M; Rinke A; Pöpperl G; Lehnert H; Izbicki JR; Krausch M; Vashist YK; Raffel A; Bürk CG; Hoffmann J; Goretzki P; Pape UF;
Zentralbl Chir; 2014 Jun; 139(3):276-83. PubMed ID: 23042103
[TBL] [Abstract][Full Text] [Related]
31. Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force.
Koumarianou A; Filosso PL; Bodei L; Castano JP; Fernandez-Cuesta L; Deroose CM; Foll M; Dromain C; Reed NS; Caplin M; Capdevila J; Falkerby J; Faggiano A; Frilling A; Grande E; Hicks RJ; Kasajima A; Kos-Kudla B; Krishna BA; Lim E; Rinke A; Singh S; Thirlwell C; Volante M; Walter T
J Neuroendocrinol; 2024 May; ():e13412. PubMed ID: 38754956
[TBL] [Abstract][Full Text] [Related]
32. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
[TBL] [Abstract][Full Text] [Related]
33. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
34. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
[TBL] [Abstract][Full Text] [Related]
35. Finding the Appropriate Therapeutic Strategy in Patients with Neuroendocrine Tumors of the Pancreas: Guideline Recommendations Meet the Clinical Reality.
Krug S; Damm M; Garbe J; König S; Schmitz RL; Michl P; Schrader J; Rinke A
J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300189
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Lamarca A; Elliott E; Barriuso J; Backen A; McNamara MG; Hubner R; Valle JW
Cancer Treat Rev; 2016 Mar; 44():26-41. PubMed ID: 26855376
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
Oberg K
Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
[TBL] [Abstract][Full Text] [Related]
38. Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs).
Megdanova-Chipeva VG; Lamarca A; Backen A; McNamara MG; Barriuso J; Sergieva S; Gocheva L; Mansoor W; Manoharan P; Valle JW
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708210
[TBL] [Abstract][Full Text] [Related]
39. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
[TBL] [Abstract][Full Text] [Related]
40. Emerging therapies for pancreas neuroendocrine cancers.
Mahjoub AR; O'Reilly EM
Chin Clin Oncol; 2013 Sep; 2(3):23. PubMed ID: 25841679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
